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Purpose: This paper reviews the clinical course of a case of severe Crohn’s disease and discusses 
the scientific ramifications of a novel treatment approach.
Patients and methods: A case study of a 37-year-old male with a 22-year history of Crohn’s 
disease whose clinical course had experienced no sustained remissions. The patient was treated 
with a protocol that utilized serotonin and dopamine amino acid precursors administered under 
the guidance of organic cation transporter assay interpretation.
Results: Within 5 days of achieving the necessary balance of serotonin and dopamine, the 
patient experienced remission of symptoms. This remission has been sustained without the use 
of any Crohn’s disease medications.
Conclusion: In Crohn’s disease, it is known that there is an increase of both synthesis and 
tissue levels of serotonin in specific locations. It is asserted that this is prima facie evidence 
of a   significant imbalance in the serotonin–dopamine system, leading to serotonin toxicity. 
The hypothesis formulated is that improperly balanced serotonin and dopamine transport, 
  synthesis, and metabolism is a primary defect contributing to the pathogenesis of Crohn’s 
disease.
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Introduction
Symptoms of Crohn’s disease in patients range on a spectrum from mild to very 
severe. Symptoms include diarrhea, abdominal pain, intermittent fever, rectal bleeding, 
loss of appetite, significant weight loss, arthralgias, fatigue, malaise, and headaches. 
  Involvement of other organ systems beyond the intestinal tract, such as eyes, skin, 
and liver, may be present.1
As there is currently no known cure, treatment is focused on symptom control. 
Complications secondary to medications prescribed for symptom control may occur. 
When the disease fails to respond to the milder medications, more aggressive medica-
tions are prescribed. Medication complications can be severe, including infections, 
serum sickness, drug-induced lupus, diabetes, cancers, and even death.2
This paper documents a case study of a patient with severe Crohn’s disease. The 
patient had suffered with Crohn’s disease of progressing severity for 22 years, dur-
ing which time no sustained remission of symptoms was noted. The patient suffered 
profound complications from   infliximab, 6-mercaptopurine, and prednisone. He 
experienced no sustained response from mesalamine, low-dose naltrexone, or dietary 
modification. The patient’s clinical course was complicated by steroid-induced insulin-
dependent diabetes. He also suffered from severe weight loss, depression, fatigue, mal-Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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aise, headaches, purulent-mucinous diarrhea, rectal bleeding, 
bilious vomiting, and diffuse arthralgias. Complaints of back 
pain resulted in back surgery with negative operative findings 
and no relief of symptoms. Exploratory gallbladder surgery 
was done in response to abdominal pain. The pathologist’s 
report of tissue submitted from the gallbladder surgery was 
negative for any pathology. In February 2004, the patient had 
progressed to the most severe state of his disease,   losing 25% 
of his body weight. The patient was fully disabled and unable 
to work. He experienced constant symptoms of Crohn’s dis-
ease despite attempts at medication alteration. At all times 
from his first confirmed attack of Crohn’s disease in 1990 at 
age 19 years, he was on one or more prescription drugs to 
try to control the disease symptoms.
The patient achieved full remission of symptoms in a 
matter of days once the proper orally administered serotonin 
and dopamine amino acid precursor dosing values were estab-
lished with the guidance of urinary organic cation transporter 
(OCT) functional status determination (herein referred to as 
OCT assay interpretation).
Material and methods
The patient was treated with a novel treatment protocol devel-
oped by NeuroResearch Clinics (Duluth, Minnesota, MN, 
USA). Peer-reviewed publications from 20093,4 and 20105–7 
outlined a novel “three-phase model” of OCT response to 
simultaneous administration of serotonin and dopamine 
amino acid precursors in significant amounts, which is the 
basis for OCT assay interpretation. Outlined in this paper 
is a proposed novel OCT model that potentially describes 
the etiology of the “three-phase response” of serotonin and 
dopamine during simultaneous administration of their amino 
acid precursors in varied daily dosing values.5
The protocol
Serotonin and dopamine exist in two states. The endogenous 
state is found when no amino acid precursors are being 
administered. The competitive inhibition state is found when 
significant amounts of amino acid precursors of both serotonin 
and dopamine are administered simultaneously. This novel 
approach places serotonin and dopamine in the   competitive 
inhibition state and then optimizes their   transport in proper 
balance through the OCTs with OCT analysis   interpretation. 
The approach was developed by medical research that started 
in 1997. Peer-reviewed research covering methodology, appli-
cations, and the scientific foundation of this novel approach 
was published in 20093,4 and 2010.5–7   Optimization of the 
serotonin–dopamine system has applications in any condition 
where an imbalance between serotonin and dopamine in 
transport, synthesis, or metabolism is   present. The potential 
scope of applications is far-reaching.
The protocol utilized for treatment of Crohn’s disease 
consisted of the amino acid dosing values listed in Table 1. 
This protocol has been covered in previous peer-reviewed 
research.3,7
The initial step of the protocol is the simultaneous admin-
istration of serotonin and dopamine amino acid precursors 
with no OCT functional status determination in order to place 
the system into a competitive inhibition state. Three dosing 
levels were available, as noted in Table 1. At the first visit, the 
patient was started on level 1 amino acid dosing. The patient 
was then followed weekly for evaluation of response to the 
start or change in amino acid dosing levels. As described in 
the results section of this paper, dosing was implemented as 
per Table 1. The patients took the amino acid dosing values 
of each level at the times indicated in Table 1.
If the patient failed to achieve full relief of symptoms on 
level 3 dosing, a urine sample was collected and submitted 
for urinary serotonin and dopamine laboratory assay. This 
was followed by OCT assay interpretation. Based on OCT 
assay interpretation, the amino acid precursors of serotonin 
and dopamine were adjusted in an effort to achieve full relief 
of symptoms or a balance of urinary serotonin and dopamine 
in the Phase 3 therapeutic range, whichever came first.3,7
OCT assay interpretation
The serotonin and dopamine filtered at the glomerulous are 
metabolized by the kidneys, and significant amounts do not 
make it to the final urine. Serotonin and dopamine found 
in the urine are monoamines synthesized in the proximal 
  convoluted renal tubule cells and have never been found in 
the central nervous system or peripheral system. Serotonin 
and dopamine that are newly synthesized by the kidneys meet 
one of two fates. Urinary serotonin and dopamine levels are 
primarily dependent on the interaction of the basolateral 
monoamine transporters (OCT2s) and the apical mono-
amine transporters (OCTN2s) of the proximal convoluted 
Table 1 Individual dosing value: milligrams of L-tyrosine/milligrams 
of 5-hydroxytryptophan*
Level AM Noon 4 PM 7 PM
Level 1 1500/150 1500/150
Level 2 1500/150 1500/150 1000/300
Level 3 1500/150 1500/150 1000/300 1000/300
Note: *The patient also received the following daily dosing values: 1000 mg of 
vitamin C, 220 mg of calcium citrate, 75 mg of vitamin B6, 400 μg of folate, 4500 mg 
L-cysteine, and 400 μg of selenium.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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renal tubule cells of the kidneys.5,8 The OCTN2s8 of the 
proximal convoluted renal tubule cells transport serotonin 
and dopamine that is not transported by the OCT2.5 While 
in the competitive inhibition state, serotonin and dopamine 
not transported by the OCT2s are found in the final urine as 
waste.6 Although there are numerous other forces that inter-
act with the newly synthesized renal monoamines, they are 
small compared with the effects of these transporters.5 Proper 
interpretation of urinary serotonin and dopamine levels in 
the competitive inhibition state determines the functional 
status of the OCT2s of the proximal convoluted renal tubule 
cells of the kidneys, known as OCT assay interpretation. 
The OCT2s exist in three different phases dependent on the 
status of the entrance gate and lumen saturation.3–7 Table 2 
outlines the correlation between entrance gate status and 
lumen saturation.
The basis for OCT assay interpretation requires that the 
system be placed into the competitive inhibition state and 
then two or more urinary serotonin and dopamine assays 
performed while taking serotonin and dopamine amino acid 
precursors at significantly varied dosing values. The results 
are then compared in order to determine the change in urinary 
serotonin and dopamine levels in response to the change in 
amino acid precursor dosing values.3–7
Urinary serotonin and dopamine values found on assay 
were reported in micrograms of monoamine per gram of 
creatinine in order to compensate for fluctuations in urinary-
specific gravity. A urinary serotonin or dopamine value 
less than 80 or 475 μg of monoamine per 1 g of creatinine, 
  respectively, is defined as a Phase 2 response. A urinary 
serotonin or dopamine value greater than 80 or 475 μg of 
monoamine per 1 g of creatinine, respectively, is interpreted 
as being in Phase 1 or Phase 3. Differentiation of Phase 1 from 
Phase 3 is a follows. If a direct relationship is found between 
amino acid dosing and urinary assay response, it is referred 
to as a Phase 3 response. An inverse relationship is referred 
to as a Phase 1 response. The Phase 3 therapeutic range for 
urinary serotonin is defined as 80–240 μg of serotonin per 
1 g of creatinine. The Phase 3 therapeutic range for urinary 
dopamine is defined as 475–1100 μg of dopamine per 1 g 
of creatinine.3,5–7
Processing, management, and assay of the urine samples 
collected for this study were as follows. Urine samples were 
collected 6 hours prior to bedtime with 4:00 PM being the 
most frequent collection time point. The samples were stabi-
lized in 6 N hydrochloric acid to preserve the dopamine and 
serotonin. The urine samples were collected after a minimum 
of 1 week, during which the patient was taking a specific daily 
dosing of amino acid precursors of serotonin and dopamine. 
No doses were missed. Samples were shipped to DBS Labo-
ratories (Duluth, MN). Urinary dopamine and serotonin were 
assayed utilizing commercially available radioimmunoassay 
kits (3 CAT RIA IB88501 and IB89527, both from Immuno 
Biological Laboratories, Inc., Minneapolis, MN). The DBS 
laboratory is accredited by Clinical Laboratory Improvement 
Amendments as a high-complexity   laboratory. OCT assay 
interpretation was performed. Results were reported in micro-
grams of monoamine per gram of creatinine to compensate 
for specific gravity variances in the urine.
Results
An endoscopy examination, prior to treatment with amino 
acids while the disease was active, was performed in 
  September 2005. Results revealed several apthous ulcers in 
the terminal ileum. Tissue biopsy confirmed this diagnosis.
At the initiation of the amino acid protocol, the patient 
was still taking mesalamine, low-dose naltrexone, and 
escitalopram. The patient reported no relief of symptoms 
after any of these drugs were started. The escitalopram was 
discontinued at the start of amino acid treatment, and the 
mesalamine and low-dose naltrexone were continued.
At the first visit, the patient was started on level 1 
amino acid dosing as per Table 1. One week later there 
was no change in symptoms, and the patient’s amino acid 
dosing values were increased to level 2 (see Table 1). The 
patient achieved lessening of the symptoms when he was 
on level 2 amino acid dosing. At that point, the patient 
revealed that he felt that this approach was the best treat-
ment he had experienced during the course of his 22-year 
illness. The amino acids were increased to level 3 dosing 
(see Table 1), with no further change in symptoms. After 
1 week of level 3 dosing, a urine sample was obtained and 
analyzed. The reported values were then submitted for OCT 
assay interpretation.
Table  2  The  following  considerations  exist  with  regard  to 
the basolateral monoamine organic cation transporters of the 
proximal convoluted renal tubule cells*
Phase 1 Phase 2 Phase 3
Serotonin or dopamine 
transporter entrance gates
Partially closed Open Open
Transporter lumen 
saturation
Unsaturated Unsaturated Saturated
Note: *In Phase 1, the serotonin and dopamine gates are partially closed, restricting 
access to the transporter. In Phases 2 and 3, the gates are open, allowing full 
access to the transporter by serotonin and dopamine. In Phases 1 and 2, the lumen 
of the transporter is not saturated with serotonin and dopamine. In Phase 3, the 
lumen of the transporter is saturated with serotonin or dopamine.5Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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When the first urine sample was collected for OCT assay 
interpretation, the patient was taking level 3 dosing: 900 mg 
5-hydroxytryptophan (5-HTP), 5000 mg L-tyrosine, and 
4500 mg L-cysteine with cofactors.
The first urinary assay revealed serotonin to be in Phase 3 
(Table 2) with a reported value of 5150.7 μg of serotonin 
per 1 g of creatinine, and a dopamine in Phase 2 (Table 2) 
with a reported value of 206.4 μg of dopamine per 1 g of 
creatinine.
After the first OCT assay interpretation, the patient’s daily 
amino acid dosing was increased by 1000 mg of L-tyrosine 
and 240 mg of L-dopa. At that point, the patient was taking 
the following in divided daily doses: 900 mg 5-HTP, 6000 mg 
L-tyrosine, 240 mg L-dopa, and 4500 mg L-cysteine with 
cofactors. After 1 week taking these new amino acid dosing 
values, there was no change in the patient’s symptoms.
A second urine sample was submitted for analysis, 
followed by OCT assay interpretation. This revealed that 
the patient’s urinary serotonin was in Phase 3 (Table 2) at 
12,611.1 μg of serotonin per 1 g of creatinine, and his dop-
amine was in Phase 3 (Table 2) at 741.3 μg of dopamine per 
1 g of creatinine.
The recommendation was to decrease the daily 5-HTP 
dosing by 300 mg per day, increase L-tyrosine by 1000 mg 
per day, and continue other amino acids as before. The patient 
was then taking the following in divided daily doses: 600 mg 
5-HTP, 7000 mg L-tyrosine, 240 mg L-dopa, and 4500 mg 
L-cysteine with cofactors.5 Within 1 week of this dosing 
value change, the patient became asymptomatic, indicat-
ing that adequate OCT balance of the serotonin–dopamine 
system had occurred. The patient’s response and remission 
with amino acid treatment was very impressive and relatively 
abrupt compared with the 22-year course of his disease. This 
profound resolution of symptoms was achieved within 6 
weeks of the first clinic visit.
The patient noted the return of solid stools, no further 
vomiting, restored energy, increased motivation, and resolu-
tion of depression symptoms. All prescription medications 
that the patient had been taking since the start of amino acid 
treatment were discontinued after 6 weeks of amino acid 
treatment, including mesalamine and naltrexone, with no 
return of symptoms. The amino acid dosing values that had 
induced relief of symptoms were continued.
Following remission of symptoms, the patient’s sedimen-
tation rate returned to the normal range. His weight stabi-
lized at approximately 20 pounds above the lowest weight 
attained while disease symptoms were present. The patient 
reported that he was very comfortable at that weight. The 
patient found that if he missed a dose of the amino acids, 
some of the Crohn’s disease symptoms would return.
A third OCT assay interpretation was obtained 5 months 
later with amino acid dosing values that induced relief of 
symptoms. Urinary serotonin was reported as 9019.5 μg of 
serotonin per 1 g of creatinine and urinary dopamine was 
604.3 μg of dopamine per 1 g of creatinine; both were in 
Phase 3 (Table 2). At this point, the patient was still asymp-
tomatic. The recommendation was to decrease the daily 
5-HTP dosage to 300 mg, decrease L-tyrosine dosing by 
1000 mg per day, and continue other amino acids as before. 
After this dosing value change, the patient was then taking 
the following in divided daily doses: 300 mg 5-HTP, 6000 mg 
L-tyrosine, 240 mg L-dopa, and 4500 mg L-cysteine with 
cofactors. Following this change in amino acid dosing values, 
the patient continued to be asymptomatic, a state that exists 
to this day as long as he is compliant with the prescribed 
amino acid dosing values.
Endoscopy subsequent to remission of symptoms was 
performed in March 2010. This was 26 months after starting 
the amino acid protocol guided by OCT assay interpreta-
tion and 24 months after achieving relief of symptoms. This 
endoscopy was performed by the same gastroenterologist 
that performed endoscopy prior to remission of symptoms. 
At this endoscopy, the patient was taking his amino acids 
daily with no prescription medications. He was taking no 
insulin or oral hypoglycemic agents, and his HbA1c had 
returned to normal. There were no signs of diabetes or other 
illnesses. He had returned to full-time gainful employment, 
after a period of over 4 years during which he was fully 
disabled.
The gastroenterologist reported that for the first time in 
10 years of caring for the patient, the Crohn’s disease was in 
complete remission. This finding was verified by the patholo-
gist after review of tissue samples submitted.
As of the time of writing this paper, the patient continues 
to do well with no infections or adverse reactions. He is gain-
fully employed and living a normal life. All follow-up testing, 
including sedimentation rates, have been normal.
Discussion
Scientific basis
The authors have documented a number of patients with 
Crohn’s disease who experienced similar remission of symp-
toms with this approach. This case was selected for this paper 
due to the severity of disease in the patient.
Serotonin and dopamine levels inside and outside of the 
cell structures containing them are primarily a function of Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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transporter status.5 The question raised is how OCT assay 
interpretation of renal transporters relates to the OCTs of the 
gastrointestinal (GI) tract. The hypothesis is that performing 
OCT assay interpretation on one set of OCTs will give insight 
into transport of serotonin, dopamine, and their precursors 
at other OCTs throughout the body. Within 3–5 days of 
starting or changing amino acid precursor dosing values, 
serotonin, dopamine, and their precursors reach equilibrium 
throughout the body.3,5–7 At equilibrium, amino acid precur-
sors, serotonin, and dopamine exert similar effects at cation 
transporters throughout the body.
In the competitive inhibition state, the serotonin and 
dopamine systems function as one system in transport, syn-
thesis, and metabolism. Affecting change to one system will 
affect both systems in their functions. Serotonin, dopamine, 
and their amino acid precursors compete for transport at the 
OCTs. Significant increases in one monoamine will decrease 
monoamine and precursor transport of the other system 
through competitive inhibition. Transport of precursors into 
the cells is required in order to place them in an environment 
where synthesis takes place. The same enzyme, the L-aromatic 
amino acid decarboxylase enzyme (AAAD), is responsible for 
synthesis of serotonin and dopamine. Creating an environment 
where precursors of one system are significantly increased 
without significantly increasing the precursors of the other 
system leads to decreased access to the AAAD by precursors 
of the other system, with associated decreased synthesis or 
depletion due to competitive inhibition. Both serotonin and 
dopamine are metabolized by the monoamine oxidase (MAO) 
enzyme system. A significant increase in levels of one system 
will increase MAO activity, leading to increased metabolism 
and depletion of the other system.2,5,6
In the intestinal tract of Crohn’s patients there is exces-
sive synthesis with associated increased tissue levels of 
serotonin.8,9 In Crohn’s disease, high levels of serotonin 
dominate synthesis, metabolism, and transport, leading to 
dopamine and catecholamine levels that are low relative to 
the balance needed to function properly with the serotonin 
levels present.3,5
OCT assay interpretation
As noted in previous peer-reviewed research by the authors, 
OCT phase determination defines the status of the sero-
tonin and dopamine gates at the entrance to the basolateral 
monoamine OCT (open or partially closed) of the proximal 
convoluted renal tubule cells of the kidneys and the status 
of serotonin and dopamine saturation in these transporters 
(see Table 2).5
Proper interpretation of the findings requires the following 
explanation. Serotonin and dopamine both need to be in the 
competitive inhibition state when OCT assay interpretation is 
performed. This means that significant dosing values of both 
serotonin and dopamine need to be administered simultane-
ously. When in the competitive inhibition state, serotonin and 
dopamine are in full competition for transport, synthesis, and 
metabolism.3,5 Testing of the urine is only done after amino 
acid precursors of the monoamines are started in accordance 
with the protocol, placing the serotonin–dopamine system 
in the competitive inhibition state. Baseline testing in the 
endogenous state prior to administration of amino acid 
precursors is of no value, as these assay levels correlate 
with nothing. As noted in previous peer-reviewed literature, 
baseline testing of urinary serotonin and dopamine does not 
correlate with baseline assays performed on   subsequent days 
in the same individual.6
Simply giving the patient one or more amino acid pre-
cursors is not the key to optimal outcomes. The OCT needs 
to be challenged with serotonin and dopamine precursors 
in significant amounts to place transport in the competitive 
inhibition state so that proper OCT assay interpretation can 
be realized.5
The OCTN
There is a known genetic defect of OCTN1 and OCTN2 in 
the colon of patients suffering from Crohn’s diease.9 All 
OCT and OCTN transporters are capable of transporting 
organic cations, including serotonin, dopamine, and their 
precursors.8 In Crohn’s disease, the serotonin content of 
the mucosa and submucosa of the proximal and distal 
colon is increased.10 Increased synthesis of serotonin is 
known to be associated with Crohn’s disease.11 No reason-
able explanation of the etiology of serotonin elevation in 
the colon tissue of Crohn’s disease patients has been put 
forth previously.
It is postulated that the known OCTN1 and OCTN2 genetic 
deficit may be tied to the increased synthesis and tissue levels 
of serotonin seen with Crohn’s disease. Based on OCT assay 
interpretation, it appears that a severe imbalance between 
serotonin and dopamine transport, synthesis, and metabolism 
is at the heart of Crohn’s disease.
An imbalance of the serotonin–dopamine transport sys-
tem has been linked to numerous diseases.3,5–7 It is proposed 
that much of the clinical constellation found with Crohn’s 
disease may be induced by a serotonin toxicity of the colon 
exacerbated by relatively low levels of dopamine resulting 
from defective OCTN transport.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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In the GI tract, serotonin is contained primarily in the 
enteroendocrine cells (ECs). The serotonin–dopamine trans-
porter balance of the ECs controls paracrine–autocrine and/or 
endocrine mediators that modulate GI function.12 It is asserted 
that proper treatment needs to include correct management of 
the serotonin and dopamine imbalance in transport, synthesis, 
and metabolism. The only definitive way to address these 
problems optimally is with OCT analysis interpretation in 
the competitive inhibition state that is established with proper 
amino acid precursor administration.
It is postulated that the patient’s Crohn’s disease was 
impacted in a positive manner as follows. It is known that 
there is increased synthesis of serotonin with increased 
serotonin levels in the proximal and distal colon.11 Levels 
of the serotonin–dopamine system are impacted primarily 
by synthesis, uptake, and metabolism. For serotonin and 
dopamine to be synthesized, their amino acid precursors need 
to be transported into the structures where this occurs. There 
appears to be a defect in transport of serotonin precursors of 
the colon. Serotonin precursors are transported preferentially 
at the exclusion of dopamine precursors, leading to high 
levels of synthesis, high levels of serotonin in portions of the 
colon, and compromise of catecholamine synthesis. Properly 
balancing the serotonin and dopamine precursor transport 
leads to a decrease in serotonin synthesis, less serotonin in 
the tissue of the proximal and distal colon, and an increase 
in synthesis of dopamine, norepinephrine, and   epinephrine. 
Increased serotonin levels of Crohn’s disease lead to 
increased MAO activity, which without reciprocal increases 
of the catecholamines leads to increased metabolism of the 
catecholamines, further exacerbating the imbalance.
Other implications
With a case study such as this there is always the possibility 
that remission was coincidental to treatment. This patient had 
a 22-year history of progressively worsening Crohn’s with no 
remissions and has been free of Crohn’s disease symptoms 
clinically and on biopsy for 2.5 years since the appropriate 
dosing values of serotonin and dopamine amino acids were 
established. We leave it to the reader to speculate as to the 
odds of this being a spontaneous coincidental remission 
versus a response to properly balanced amino acids.
One other aspect of the patient’s treatment needs to 
be discussed. The patient was suffering from depression. 
  Previously published peer-reviewed literature by the authors 
indicates that this same approach with OCT assay interpreta-
tion for treatment of depression is effective.3,7 In this case 
study, the patient’s depression resolved when the serotonin 
and dopamine were balanced to the degree needed for relief of 
Crohn’s disease symptoms. It is asserted that it was no coin-
cidence that the patient’s depression resolved simultaneously 
with the resolution of the symptoms of Crohn’s disease.
Conclusion
In recent years, a genetic defect of the OCTN1 and OCTN2 of 
the colon has been identified in patients with Crohn’s disease. 
The OCTN1 and OCTN2 are responsible for transport of cat-
ions, including the monoamines of the serotonin–dopamine 
system and their precursors. It is known with Crohn’s disease 
patients that there is a marked increased in serotonin levels 
of the proximal and distal colon associated with a defect 
in serotonin synthesis. It remains to be proven whether a 
transport problem exists in the serotonin–dopamine system 
induced by the OCTN1 and OCTN2 genetic defect found 
in Crohn’s disease. For now, these observations cannot be 
overlooked. Clearly, further studies relating to OCT analysis 
interpretation and the OCTN transporters of the colon as they 
relate to other abnormal findings associated with Crohn’s 
disease are indicated.
This paper potentially opens the door to a new area of 
treatment and study in Crohn’s disease patients. The goal 
of the paper is to stimulate further interest in these findings 
in order to duplicate, confirm, and invite scrutiny of these 
results.
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